News | July 21, 2025
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Subscribe To Our Newsletter & Stay Updated
